[go: up one dir, main page]

WO2008118141A3 - Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy - Google Patents

Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy Download PDF

Info

Publication number
WO2008118141A3
WO2008118141A3 PCT/US2007/022464 US2007022464W WO2008118141A3 WO 2008118141 A3 WO2008118141 A3 WO 2008118141A3 US 2007022464 W US2007022464 W US 2007022464W WO 2008118141 A3 WO2008118141 A3 WO 2008118141A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
combination
adjunctive therapy
cannabinoid
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/022464
Other languages
French (fr)
Other versions
WO2008118141A2 (en
Inventor
Ethan S Burstein
Luis R Gardell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of WO2008118141A2 publication Critical patent/WO2008118141A2/en
Publication of WO2008118141A3 publication Critical patent/WO2008118141A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions that contain a compound that modulate the activity of a cannabinoid receptor in conjunction with another therapeutic compound and uses of compounds that modulate the activity of a cannabinoid receptor in conjunction with another therapeutic compound to treat various conditions (e.g., side effects).
PCT/US2007/022464 2006-10-17 2007-10-17 Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy Ceased WO2008118141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85262206P 2006-10-17 2006-10-17
US60/852,622 2006-10-17

Publications (2)

Publication Number Publication Date
WO2008118141A2 WO2008118141A2 (en) 2008-10-02
WO2008118141A3 true WO2008118141A3 (en) 2008-12-24

Family

ID=39731088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022464 Ceased WO2008118141A2 (en) 2006-10-17 2007-10-17 Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy

Country Status (1)

Country Link
WO (1) WO2008118141A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9193694B2 (en) 2011-07-01 2015-11-24 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960376B2 (en) 2007-09-14 2011-06-14 Cara Therapeutics, Inc. Benzo-fused heterocycles
JP2011162472A (en) * 2010-02-09 2011-08-25 Nippon Soda Co Ltd Nitrogen-containing heterocyclic compound or salt thereof, and germicide for agriculture and horticulture
ES2529119T3 (en) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Condensed heterocyclic compounds as ion channel modulators
CN102807574B (en) * 2011-05-30 2015-09-02 长春吉大天元化学技术股份有限公司 New pyridine sulphur nitrogen seven-membered ring derivative as antitumor drug, and its preparation method and application
NO3175985T3 (en) 2011-07-01 2018-04-28
US20130337052A1 (en) * 2012-06-19 2013-12-19 Patricia Linert System and Method of Reducing Impairment of Alertness, Concentration, Motivation, and Creativity Caused by Medication
SG11201607268UA (en) 2014-03-13 2016-09-29 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US20180147141A1 (en) * 2016-11-29 2018-05-31 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
CA3154630A1 (en) 2019-10-21 2021-04-29 Mark E. Duggan 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propano ic acid derivatives as h1 and 5-ht2a-receptor modulators for the treatment of sleep disorders
EP4619394A1 (en) 2022-11-16 2025-09-24 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
CN120202195A (en) 2022-11-16 2025-06-24 巴斯夫欧洲公司 Substituted benzodiazepines as fungicides
EP4619393A1 (en) 2022-11-16 2025-09-24 Basf Se Substituted benzodiazepines as fungicides

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049652A1 (en) * 2000-12-20 2002-06-27 Astrazeneca Ab Method of treatment
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
WO2005000809A1 (en) * 2003-06-11 2005-01-06 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
WO2005002586A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005063254A2 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
WO2005115977A1 (en) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Pyrrolidine derivatives as cb1-receptor antagonists
WO2006107948A2 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007018460A1 (en) * 2005-08-08 2007-02-15 Astrazeneca Ab Therapeutic agents
WO2007047737A1 (en) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049652A1 (en) * 2000-12-20 2002-06-27 Astrazeneca Ab Method of treatment
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
WO2005000809A1 (en) * 2003-06-11 2005-01-06 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
WO2005002586A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005063254A2 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
WO2005115977A1 (en) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. Pyrrolidine derivatives as cb1-receptor antagonists
WO2006107948A2 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007018460A1 (en) * 2005-08-08 2007-02-15 Astrazeneca Ab Therapeutic agents
WO2007047737A1 (en) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSON JEFFREY J ET AL: "Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 295, no. 2-3, 1996, pages 163 - 168, XP002495957, ISSN: 0014-2999 *
MUCCIOLI G G ET AL: "Current knowledge on the antagonists and inverse agonists of cannabinoid receptors", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 12, no. 12, 1 January 2005 (2005-01-01), pages 1361 - 1394, XP008082642, ISSN: 0929-8673 *
ROGERS-EVANS M ET AL: "Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis", QSAR AND COMBINATORIAL SCIENCE 200407 DE, vol. 23, no. 6, July 2004 (2004-07-01), pages 426 - 430, XP002495955, ISSN: 1611-020X *
SEGOVIA GREGORIO ET AL: "Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.", MOVEMENT DISORDERS : OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY FEB 2003, vol. 18, no. 2, February 2003 (2003-02-01), pages 138 - 149, XP002495956, ISSN: 0885-3185 *
SUNDRAM S ET AL: "Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat accumbens", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 371, 2 July 2005 (2005-07-02), pages 428 - 433, XP002420595, ISSN: 0028-1298 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371329B2 (en) 2009-07-27 2016-06-21 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US9193694B2 (en) 2011-07-01 2015-11-24 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US10377748B2 (en) 2015-09-15 2019-08-13 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10392379B2 (en) 2015-09-15 2019-08-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10766890B2 (en) 2015-09-15 2020-09-08 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US10968211B2 (en) 2015-09-15 2021-04-06 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11814376B2 (en) 2015-09-15 2023-11-14 Assembly Biosciences, Inc. Hepatitis b core protein modulators
US10987360B2 (en) 2016-09-15 2021-04-27 Assembly Biosciences, Inc. Hepatitis B core protein modulators
US11078170B2 (en) 2017-03-02 2021-08-03 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
US11040965B2 (en) 2017-03-13 2021-06-22 Assembly Biosciences, Inc. Process for making Hepatitis B core protein modulators

Also Published As

Publication number Publication date
WO2008118141A2 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2008118141A3 (en) Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2007109330A3 (en) S1p receptor modulating compounds
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
MX2008011684A (en) Imidazolothiazole compounds for the treatment of disease.
WO2009076454A3 (en) Compounds that modulate intracellular calcium
ECSP067043A (en) USEFUL PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2008070268A3 (en) Pharmaceutical compositions
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2005016286A8 (en) Pyrazine modulators of cannabinoid receptors
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
WO2009035818A8 (en) Compounds that modulate intracellular calcium
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
PL1979355T3 (en) Spiro imidazole derivatives as ppar modulators
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2007024717A3 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
BRPI0509207A (en) cannabinoid tetrahydro-indazole modulators
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
NO341679B1 (en) Substituted pyridylamide compounds, preparation of such and pharmaceutical compositions containing them, and use as modulators of the histamine H3 receptor
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873455

Country of ref document: EP

Kind code of ref document: A2